Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study

Abstract Background We conducted a phase II study of carboplatin plus nab‐paclitaxel for the treatment of small cell lung cancer (SCLC) after the failure of a prior standard chemotherapy containing platinum, etoposide, irinotecan, and amrubicin if indicated. Patients with interstitial pneumonia comp...

Full description

Bibliographic Details
Main Authors: Naoya Ikeda, Ryo Arai, Sayo Soda, Takashi Inoue, Nobuhiko Uchida, Yusuke Nakamura, Meitetsu Masawa, Yoshitomo Kushima, Hiroaki Okutomi, Akihiro Takemasa, Yasuo Shimizu, Seiji Niho
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Thoracic Cancer
Subjects:
carboplatin
interstitial pneumonia
nab‐paclitaxel
small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14394

Internet

https://doi.org/10.1111/1759-7714.14394

Similar Items